Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The value of circulating microRNAs for early diagnosis of B-cell lymphoma: A case-control study on historical samples

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Jorne L Biccler
  • Kerry J Savage
  • Peter D N Brown
  • Judit Jørgensen
  • Thomas S Larsen
  • Christian B Poulsen
  • Danny Stoltenberg
  • Laurie H Sehn
  • David W Scott
  • Alina S Gerrie
  • Lasse H Jakobsen
  • Martin Bøgsted
  • Tarec C El-Galaly
  • Diego Villa
View graph of relations

In this study, we analyzed the evolution of the prognosis of primary central nervous system lymphoma (PCNSL) patients as they reach selected progression-free survival (PFS) milestones after high-dose methotrexate (HD-MTX)-based therapy. In total, 258 and 146 patients were included from Denmark and British Columbia, respectively. All patients were diagnosed during 2000-2017. The 5-year PFS was 27% (95% CI 23; 32); however, for patients reaching 5 years of PFS, this increased to 71% (95% CI 57; 86). Within the first 5 years after diagnosis, patients lost 2.0 years (95% CI 1.8; 2.2) when compared to a similar background population. This reduced to 0.5 years (95% CI 0.2; 0.9) for patients reaching 5 years of PFS. Treatment with rituximab was associated with improved outcomes. The prognosis of patients with PCNSL treated with HD-MTX-based regimens in this cohort is poor, although it improves as patients survive without progression/relapse. However, survival does not conclusively normalize to that of a similar background population.

Original languageEnglish
JournalLeukemia and Lymphoma
Volume60
Issue number10
Pages (from-to)2516-2523
Number of pages8
ISSN1042-8194
DOIs
Publication statusPublished - Oct 2019

ID: 59260620